|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
eliglustat
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:ATCCode
|
A16AB14
|
|
gptkbp:CASNumber
|
491833-29-5
|
|
gptkbp:chemicalFormula
|
C23H36N2O4
|
|
gptkbp:contraindication
|
severe hepatic impairment
CYP2D6 poor metabolizers with strong or moderate CYP3A inhibitors
hypersensitivity to eliglustat
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:drugClass
|
substrate reduction therapy
|
|
gptkbp:form
|
capsule
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Sanofi_Genzyme
|
|
gptkbp:mechanismOfAction
|
glucosylceramide synthase inhibitor
|
|
gptkbp:pregnancyCategory
|
Not recommended
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
abdominal pain
constipation
fatigue
headache
palpitations
flatulence
dyspepsia
upper abdominal pain
|
|
gptkbp:usedFor
|
gptkb:Gaucher_disease_type_1
|
|
gptkbp:bfsParent
|
gptkb:Cerezyme
gptkb:Sanofi_(after_2004)
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cerdelga
|